Objective: No guidelines or randomized trials address best practices for hormone therapy (HT) discontinuation. Methods: We conducted a survey study to explore HT discontinuation practices at Group Health and Harvard Vanguard, large integrated health systems in the Northwest and Northeast United States, focusing on differences between specialties and study site.
P ublication of the Women's Health Initiative (WHI) estrogen plus progestin (EPT) and estrogen-only trials led to a dramatic decrease in the number of women using hormone therapy (HT).
1<3 Within 8 months, 56% of HT users surveyed at a large California integrated healthcare delivery and coverage system reported attempting to quit HT, 2 74% quit successfully, whereas 26% resumed HT. 4 After the WHI EPT study was published, use of HT declined by 18% per quarter (July 2002 through May 2003) among women aged 50 to 74 years enrolled in the San Francisco Mammography Registry, 3 and in a multicenter study, EPT use declined by 46% whereas estrogen use declined by 28% over 12 months (July 2002 through June 2003). 1 It seems that many women are willing to tolerate symptoms rather than take a medication with potential significant risks. However, despite the risks, 8% to 9% of women aged 40 to 80 years continue using HT. 1, 5 Most major women's health organizations recommend that HT be used primarily to treat vasomotor symptoms (VMS) and that it be used for the shortest possible duration. 6 Physician recommendations can have a strong impact on women's treatment decisions. 7 However, little is known about what HT discontinuation strategies and approaches physicians are recommending.
Physician type has been found to be associated with HT prescribing frequency, with more prescribing among obstetrician/gynecologists than among family practice physicians 8, 9 possibly because of more favorable attitudes about HT 10<17 and a stronger tendency to view menopause as an endocrine deficiency. 12 Regional differences have also been noted. Before the WHI, the prevalence of HT use had been reported as three times greater in Western than Northeastern United States. 18, 19 From 1990 to 1995, the prevalence of HT use was 25% among women aged 50 to 54 years at Harvard Pilgrim Health Care in New England and 57% among women aged 50 to 59 years at Group Health in the Pacific Northwest. 20 The reasons for these regional differences have never been elucidated.
To further explore practice-based and regional differences related to HT discontinuation, we surveyed primary care physicians and obstetrician/gynecologists at integrated health plans in the Northwest and Northeast United States to answer three questions: (1) What attitudes and approaches to HT discontinuation are most common? (2) Do attitudes and approaches differ between primary care physicians and obstetrician/gynecologists? (3) Do attitudes and approaches differ by geographic region of the country? This study builds on our prior qualitative study about post-WHI attitudes and practices that showed that physicians, overall, no longer prescribe HT for prevention and are more likely to suggest HT discontinuation. 21 
METHODS
We conducted this study at Group Health and Harvard Vanguard Medical Associates. Group Health is an integrated health plan in Washington state, with approximately 560,000 enrollees, including more than 88,000 women aged 50 to 80 years. Group Health has physicians who practice under a group model (seeing only Group Health patients) as well as network physicians for whom Group Health is one of several accepted health plans. We included physicians, physician's assistants, and nurse practitioners from both of these practice models. Harvard Vanguard Medical Associates is a large group practice consisting of 14 health centers in the Boston Metropolitan area that provides care to 300,000 patients insured by the region's major health plans as well as Medicaid and Medicare. The institutional review boards at Group Health and Harvard Vanguard Medical Associates approved the study.
We designed a self-administered mail survey to elicit information about experiences with HT, including discontinuation, decision making, attitudes, beliefs, and practice changes since the release of the WHI studies. In the first phase of this study, we conducted informational interviews with physicians to gather information about HT current practices and attitudes related to HT and HT discontinuation. 21 We then created a self-administered survey based on the results of these interviews and our prior experience with physician HT DISCONTINUATION PRACTICES surveys related to HT use. 8 The questionnaire included questions related to comfort with HT prescribing, the impact of women's characteristics (eg, past myocardial infarction, family history of breast cancer, and smoking) on HT prescribing practices, HT discontinuation practices, views about the scientific evidence related to HT safety and prescribing, impact of the WHI and the Heart and Estrogen/Progestin Study on HT prescribing practices, and demographic characteristics. We mailed a cover letter describing the study with the surveys and a $25 preincentive between December 2005 and May 2006. Nonrespondents received two reminder postcards, a third reminder with another copy of the survey, and an e-mail message with a link to an abbreviated online version of the survey. We report the results from family practice physicians, internists, and obstetrician/gynecologists who had worked at the health plan for at least 12 months at the time of the survey (roughly 22-3 y after the release of the WHI-EPT study) and had at least 50 visits per year with women aged 45 to 70 years. Physicians practicing exclusively at emergency or urgent care facilities were excluded. Nonphysician respondents (n = 109) were excluded from these analyses.
Analysis
These analyses focus on the impact of provider type and study site on responses to study questions about HT discontinuation practices, nonhormonal interventions for VMS, and provider views of women's attitudes about HT discontinuation. W 2 tests for binary outcomes (percentages) and t tests for means were used to compare differences among provider types and among study sites. Logistic regression models were used to calculate adjusted odds ratios (ORs) and 95% CIs comparing approaches to HT discontinuation, nonhormonal treatments for VMS, and attitudes about HT discontinuation between sites (Group Health and Harvard Vanguard) and physician types (family practice plus internal medicine vs obstetrician/gynecologist, analyses of physician type adjusted for provider type, and those for physician type adjusted for study site). We did not control for any other variables in the logistic models. Interactions between site and physician type were investigated by testing the addition of cross-product terms within these models. In secondary analyses, we examined the impact of the sex of the provider on HT discontinuation practices, nonhormonal interventions for VMS, and provider view of women's attitudes about HT discontinuation, using logistic regression to control for site and physician type.
RESULTS
We mailed surveys to 938 providers, 708 at Group Health and 230 at Harvard Vanguard (Fig. 1) . Response rates were 80.1% at Group Health and 73.5% at Harvard Vanguard. We excluded 109 nonphysician respondents. We also excluded 144 physician respondents (116 Group Health and 28 Harvard Vanguard) who indicated that they never prescribed HT for menopause symptoms or prevention and never counseled women about HT. These analyses are limited to the 423 family practitioners and internists and 60 obstetrician/ gynecologists who responded to our survey.
The mean age of the respondents was 48.9 years (Table 1) . Among the respondents at Group Health, 92.1% were family practitioners or internists and 7.9% were obstetrician/gynecologists, compared with 73% and 27%, respectively, at Harvard Vanguard. Primary care is principally provided by family practice physicians (79%) at Group Health and by internists (99%) at Harvard Vanguard. Significantly more obstetrician/gynecologists than family practitioners/internists were women (67% vs 41%, respectively), and significantly more physicians at Harvard Vanguard than Group Health were women (59% vs 40%, respectively). Mean years practicing at that institution and percentage employed full-versus part-time were similar by practice type and institution. Among women physicians, 52% indicated that they were premenopausal, 18% were in the menopausal transition, and 30% were postmenopausal.
Emphasis on HT discontinuation was represented by mean scores on a five-point scale, where 1 = Bencourage women to discontinue HT as soon as possible[ and 5 = Blet women use HT as long as they want[ ( Table 2) . Mean scores differed between physician types and between sites. Primary care physicians (mean, 2.2) were more likely to encourage women to discontinue HT than were obstetrician/gynecologists (mean, 2.9), and Harvard Vanguard physicians (mean, 2.0) were more likely to encourage women to discontinue HT than were Group Health physicians (mean, 2.4). Women physicians (27%) were almost twice as likely as male physicians (17%) to encourage women to discontinue HT as soon as possible (OR, 1.9; 95% CI, 1.2-3.0, adjusted for site and physician type). Most physicians chose tapering (91%) rather than immediate cessation (8%) as their main approach to discontinuing oral HT, and a majority (60%) combined strategies of decreasing dose and days per week (Table 2) . Harvard Vanguard physicians were more likely to taper pills (96%) versus trying immediate cessation compared with Group Health physicians (89%). Very few physicians (G5%) switched women to patches to assist with HT discontinuation. There was no difference in tapering versus immediate cessation by provider sex; however, female physicians (69%) were somewhat more likely than male physicians (53%) to decrease both dose and days per week (adjusted OR, 1.9; 95% CI, 1.3-2.8).
Physicians reported far less experience with tapering HT patches; 57% at Group Health and 58% at Harvard Vanguard reported no experience with tapering HT patches (60% family practitioners/internists and 41% obstetrician/gynecologists). Among those with experience tapering HT patches, 21% of family practitioners or internists and 40% of obstetrician/ gynecologists reported cutting up patches, whereas 71% of family practitioners or internists and 52% of obstetrician/ gynecologists reported increasing the days between patches.
Among Group Health physicians, 18% reported cutting up patches and 73% reported increasing days between patches. Conversely, among Harvard Vanguard physicians, 48% reported cutting up patches, and 48% reported increasing days between patches (P = 0.0002 Group Health vs Harvard Vanguard). Site-by-provider type interactions were not significant (P 9 0.05).
When asked what most strongly influenced their approach to HT discontinuation, physicians' responses differed by study site but not by practice type. For Group Health and Harvard Vanguard, respectively, 52% versus 36% used the strategies they found most helpful, 17% versus 49% relied on advice from a colleague or specialist, 23% versus 7% followed the woman's preferences, 2% versus 5% relied on an institutional protocol, and 2% versus 1% relied on guidance from research literature, with the remainder replying Bother[ or Bdon't know[ (W 2 = 52.89, P G 0.0001). We asked about a variety of approaches that may be used when a woman's hot flashes return after trying to discontinue HT ( Table 3 ). The approaches most frequently endorsed were behavioral changes (44%), increased exercise (37%), black cohosh (28%), and addition of soy to the diet (26%). Overall, only 19% of physicians recommended resuming HT; however, responses varied by both physician type and study site. Obstetrician/gynecologists were more likely to recommend drug therapies, including resuming HT (43%) or starting gabapentin (7%) or clonidine (12%), than were primary care physicians (15%, 1%, and 5%, respectively). Obstetrician/ gynecologists were also more likely to recommend behavioral changes, exercise, mind-body approaches, and acupuncture than were primary care physicians. With the exception of starting selective serotonin reuptake inhibitors (SSRIs) or clonidine, the proportion of physicians recommending each of the suggested alternative therapies was greater at Harvard Vanguard than at Group Health; however, these differences were not significant for black cohosh, exercise, phytoestrogens, supplements, or mind-body therapies. Female providers were more than twice as likely as male providers to recommend almost all nonhormonal approaches after adjusting for site and provider type, including (OR, 95% CI) SSRIs (2.1, 1.3-3.6), selective norepinephrine reuptake inhibitors (SNRIs; 3.2, 1.7-5.9), behavioral changes (4.9, 3.3-7.4), increasing exercise (2.1, 1.4-3.2), black cohosh (3.0, 1.9-4.6), soy diet (2.6, 1.7-4.0), phytoestrogen supplements (2.1, 1.2-3.6), and mind-body approaches (3.8, 2.1-7.0).
Physician impressions of women's attitudes about HT varied by physician type and study site. Among obstetrician/ gynecologists, 53% agreed or strongly agreed that most women who are using HT want to come off, compared with 38% of family practitioners/internists (Table 4) . Group Health physicians were more likely (45%) to agree or strongly agree that women wanted to come off, compared with Harvard Vanguard physicians (23%). Obstetrician/gynecologists (20%) were less likely than primary care physicians (38%) to agree or strongly agree that women would discontinue HT on their own. Physicians at Harvard Vanguard (10%) were less than half as likely as physicians at Group Health (25%) to believe that women with hot flashes want to try approaches other than HT for symptom relief, even though the proportion of physicians recommending alternative therapies was higher at Harvard Vanguard than at Group Health. There were no sexbased differences in views of women's attitudes and behaviors around HT.
DISCUSSION
In the post-WHI era, it is recommended that HT be used at the lowest possible dose and for the shortest possible time 6 ; thus, the issue of HT discontinuation has taken on new significance. In this cross-sectional survey study, we explored HT discontinuation practices within Group Health and Harvard Vanguard, large integrated healthcare delivery systems in the Northwestern and Northeastern United States, respectively, focusing on specialty and site differences. We found that both health plans lacked a standard protocol for HT discontinuation and that physicians customized approaches influenced by their personal experiences, their location, advice from colleagues, the woman's preferences, and other unknown factors. These findings highlight a need to create an evidencebased approach to HT discontinuation.
Physicians at Harvard Vanguard were more likely than those at Group Health to encourage HT discontinuation and were less likely to recommend resuming HT when a woman's symptoms returned after discontinuing HT. These findings are consistent with prior studies showing higher use of HT in the Western than Northeastern United States. 18, 19 In a 2003 US survey conducted by the American Medical Association (n = 1,614, 54% response rate), 82%, 54%, and 42% of obstetrician/gynecologists, family practitioners, and internists, respectively, indicated that they would offer EPT for short-term relief of menopause symptoms. 22 The difference we observed between institutions might reflect the disparity in the types of providers offering primary care at the two sites. However, our analyses showed quite similar responses from both family practitioners and internists at Group Health (data not shown).
We also observed more favorable attitudes about HT among obstetrician/gynecologists than among family practitioners/internists. In the American Medical Association survey, obstetrician/gynecologists were almost twice as likely as other physicians to prefer an indefinite duration of therapy, and they were more likely to view EPT as beneficial for a variety of chronic conditions including ischemic heart disease, Alzheimer disease, and colon cancer, 22 a finding supportive of our observed differences between obstetrician/ gynecologists and family practitioners/internists. Further light is shed on our findings by a report from the American College of Obstetricians and Gynecologists, which surveyed their fellows in December 2004 to May 2005. 23 In this study, 49.1% of respondents did not find the combined EPT results of the WHI convincing (58.8% men, 39.5% women), although, overall, they reported a reduction in HT prescription practice relative to their practices in 2000.
Recommendations for HT discontinuation varied between provider types and between health plans; however, most physicians at both institutions favored tapering pills over immediate cessation and tapered dose first, followed by decreasing days per week. Almost 60% of physicians had no experience with tapering patches. Patches do not have the first-pass hepatic effects associated with inflammatory and coagulation responses to HT, 24 thus warranting a better understanding of how to successfully taper patches for HT cessation. The slightly higher cost of HT patches relative to oral HT may discourage their use. We did not gather information about gels and creams.
Physicians endorsed a variety of approaches to manage VMS that return after HT discontinuation. Behavioral changes and increased exercise were the most frequently recommended alternatives, more often by Harvard Vanguard physicians and obstetrician/gynecologists than by Group Health physicians or family practitioners/internists. Alternative therapies, including black cohosh and dietary soy, were recommended more often than were SSRIs or SNRIs, a finding at odds with the current evidence, which suggests a lack of benefit of black cohosh 25 and soy 25 compared with the 50% to 60% decrease in symptoms found with some SSRIs and SNRIs relative to a 30% decrease with placebo. 26 However, the proportion of physicians endorsing these therapies was similar to those reported by Israeli and US gynecologists surveyed in 2000; about 22% reported using phytoestrogens; 23% and 12%, respectively, reported using selective estrogen receptor modulators; and 6.3% and 16.1%, respectively, reported using antidepressants to manage menopause symptoms. 27 In our study, obstetrician/gynecologists more often endorsed alternative therapies that have not shown benefit 28 than did family practitioners/internists. All provider types equally used SSRIs that randomized controlled trials have shown to be beneficial alternatives. 26 Evaluating regional differences, compared with Group Health, Harvard Vanguard physicians endorsed non-HT therapies more frequently (with the exception of SSRIs, which were recommended equally in both regions), perhaps reflecting the lower inclination of Northeast physicians to recommend HT.
Group Health physicians were more likely than Harvard Vanguard physicians to believe that most women want to discontinue HT and to try other methods; yet somewhat paradoxically, Group Health physicians were also more likely to encourage HT and less likely to endorse other approaches to managing menopause symptoms. In a 2003 US survey of randomly selected Fellows of the American College of Obstetricians and Gynecologists (n = 705, 28% response rate), Power et al 23 found that more than 90% of physicians reported that women were less likely to request HT after the media coverage of the WHI findings in 2002 and were more likely to discontinue once they started. By contrast, in our survey, only 36% of physicians believed that women would discontinue HT on their own. Compared with family practitioners and internists, obstetrician/gynecologists were less likely to believe that women would discontinue HT on their own but more likely to believe that women want to discontinue HT. Given our earlier findings that half of women who discontinued HT did so without consulting their provider, providers may be unaware of the degree to which women make independent decisions about HT use.
Lastly, we observed some sex-specific differences in approaches to HT discontinuation, including stronger inclinations to encourage women to discontinue HT as soon as possible, to use combined approaches to HT discontinuation, and to recommend nonhormonal approaches to manage menopause symptoms. These findings were independent of study site and provider practice type. The reasons for these differences are unknown, but they may indicate greater distrust of HT among female physicians in the wake of the WHI and greater comfort with approaches to treatment besides HT.
CONCLUSIONS
Although caution must be used in generalizing data from two health plans to larger regions, our findings about HT practices and beliefs support national statistics that showed greater HT use in the Northwestern than in the Northeastern United States. HT discontinuation practices were characterized by tapering of both dose and frequency of oral HT, whereas physicians were less knowledgeable about discontinuation using HT patches. Physicians, especially obstetrician/gynecologists and physicians in the Northeast, endorse the use of a wide variety of behavioral, pharmaceutical, and alternative therapies in lieu of HT. Further research is needed to guide HT discontinuation practices and to provide evidence about alternatives to HT for VMS.
